Last reviewed · How we verify

BEC2 Vaccine — Competitive Intelligence Brief

BEC2 Vaccine (BEC2 Vaccine) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Anti-idiotypic monoclonal antibody vaccine. Area: Oncology.

phase 3 Anti-idiotypic monoclonal antibody vaccine GD3 ganglioside (via anti-idiotypic mimicry) Oncology Biologic Live · refreshed every 30 min

Target snapshot

BEC2 Vaccine (BEC2 Vaccine) — Eli Lilly and Company. BEC2 is a therapeutic cancer vaccine that targets the GD3 ganglioside antigen expressed on tumor cells to stimulate an immune response against cancer.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
BEC2 Vaccine TARGET BEC2 Vaccine Eli Lilly and Company phase 3 Anti-idiotypic monoclonal antibody vaccine GD3 ganglioside (via anti-idiotypic mimicry)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Anti-idiotypic monoclonal antibody vaccine class)

  1. Eli Lilly and Company · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). BEC2 Vaccine — Competitive Intelligence Brief. https://druglandscape.com/ci/bec2-vaccine. Accessed 2026-05-15.

Build your own brief

Pick any drug + add comparators: